AXL and sarcoma: The immunogenicity and antitumor efficacy of BA3011, a conditionally active biologic (CAB) AXL-targeted antibody drug conjugate (CAB-AXL-ADC), is being investigated in a phase I/II study in different sarcoma subtypes, in monotherapy or combined with a PD-1 inhibitor (NCT03425279).